Robinson - Figure 6 - Evidence (ENHANCE) Text

If we look at the primary characteristics of patients in the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study[11] there is an important lesson for our understanding of FH patients, having nothing to do with the hypothesis that was tested in that trial or with the results. ENHANCE was an imaging study of the intimal medial thickness (IMT) of the carotid artery (carotid IMT, or cIMT) in patients treated with a statin or with a statin plus an intestinal cholesterol absorption inhibitor in widespread clinical use (ezetimibe). The design of the trial, the methodology, and the interpretation of the results are fairly well known and still the subject of ongoing discussion and debate. There are, however, a couple of interesting and important points from the trial that physicians should bear in mind when thinking about their FH patients.

• The patients enrolled in ENHANCE had a mean age of 46 and all had FH.
• At baseline, 80% of the patients had been on long-term statin therapy, and baseline imaging revealed a mean cIMT measurement that was equivalent to that of a 32-year-old white male with a serum LDL cholesterol level of 134 mg/dL.

In other words, regardless of the ENHANCE study outcomes, this can be taken as compelling evidence that effective LDL lowering in FH has a very important effect on normalizing the atherosclerosis burden to equal, or even better, that of age-matched controls. There have been several other studies in different populations – another one in a Dutch FH population[12] where again, the FH patients who had received long-term statin therapy had a cIMT measurements equal to the thickness of their spouses, whether male or female, who did not have FH. Further evidence, in other words, that long-term statin therapy really helps to reduce and slow atherosclerotic progression in FH patients.

Robinson J. J Clin Lipidol. 2011; 5(6).